Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?

Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?

Source: 
Motley Fool
snippet: 
  • Roche spent $7.1 billion on a company, primarily because of an IBD therapy.
  • Pfizer just got approval for a pill to treat ulcerative colitis.
  • Eli Lilly just reported promising trial data for its IBD therapy, mirikizumab.